ARVINAS, INC. Defined Contribution Plan, Cost
ARVINAS, INC. (ARVN) reported Defined Contribution Plan, Cost of $2.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-24
- ARVINAS, INC. defined contribution plan, cost for fiscal 2025 was $2.60M, a 23.53% decline from fiscal 2024.
- ARVINAS, INC. defined contribution plan, cost for fiscal 2024 was $3.40M, a 9.68% increase from fiscal 2023.
- ARVINAS, INC. defined contribution plan, cost for fiscal 2023 was $3.10M, a 40.91% increase from fiscal 2022.
- ARVINAS, INC. defined contribution plan, cost for fiscal 2022 was $2.20M, a 69.23% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $2.60M 10-K · filed 2026-02-24 |
| 2024-12-31 | $3.40M 10-K · filed 2026-02-24 |
| 2023-12-31 | $3.10M 10-K · filed 2026-02-24 |
| 2022-12-31 | $2.20M 10-K · filed 2025-02-11 |
| 2021-12-31 | $1.30M 10-K · filed 2024-02-27 |
| 2020-12-31 | $900.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |